[Prevention of supraventricular tachyarrhythmia and tachycardia with kordaron]

The efficacy of the preventive treatment with Cordaron was studied in patients with paroxysmal supraventricular tachyarrhythmia and tachycardia. The patients were followed up for an average period of 22.5 months. The daily dose was between 100 and 300 mg. Control examinations were performed at 4-6 week intervals and the corrected Q-T interval of the ECG was taken into account. On the 3d, 6th, 12th and 18th month the patients were examined by an ophthalmologist and the thyroid hormones were examined once in a year. The correlation between the time of onset of the arrhythmia, the dose of the drug and its prophylactic efficacy was studied as well as between the duration of the treatment, the dose of the drug and the complications. In the basic group of 18 patients with paroxysmal atrial flutter a stable lasting effect was achieved in 56% of the patients and in 22% of the patients the attacks became significantly more rare. The efficacy in the patients with paroxysmal atrial taxhycardia was 100%. The favorable results depended on the time of onset of the arrhythmia. No correlation between the supporting dose of the drug and the Q-Tc was found. Complications were found in 84% of the patients at the end of the 3-year period of the study. They were related to the duration of the treatment but not to the size of the supporting drug dose.